NCT03991780View on ClinicalTrials.gov

Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 8, 2019

Primary Completion Date

April 5, 2023

Study Completion Date

October 15, 2025

Conditions
Renal Transplant Rejection
Interventions
DRUG

Fostamatinib

All patients will be given treatment with Fostamatinib. The initial treatment dose will be 100mg of Fostamatinib twice daily for 8 weeks. If after 8 weeks the participant has not experienced any side effects and are tolerant of this dose, then the dose will increase to 150mg twice daily. This dose will continue for the duration of the study.

Trial Locations (1)

W12 0HS

Imperial College NHS Healthcare Trust, London

All Listed Sponsors
lead

Imperial College London

OTHER

NCT03991780 - Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection | Biotech Hunter | Biotech Hunter